Inflammatory muscle disease: therapeutic aspects
Identifieur interne : 002525 ( Main/Exploration ); précédent : 002524; suivant : 002526Inflammatory muscle disease: therapeutic aspects
Auteurs : Luis J. Catoggio [Argentine] ; Enrique R. Soriano [Argentine]Source :
- Best Practice & Research Clinical Rheumatology [ 1521-6942 ] ; 2000.
English descriptors
- KwdEn :
- Teeft :
- Accurate diagnosis, Active disease, Active exercise, Adequate treatment, Aggressive therapy, Aggressive treatment, American journal, Arthritis, Autoantibody, Azathioprine, Biopsy, Bone marrow suppression, British journal, Buenos aires, Case reports, Catoggio, Chloroquine, Chloroquine sulphate, Clinical improvement, Clinical practice, Combination therapy, Corticosteroid, Current management, Cyclophosphamide, Cytotoxic drugs, Dermatomyositis, Dos, Drug therapy, England journal, Experimental rheumatology, Foetal loss, Gamma globulin, High dose steroids, High doses, High risk, Hospital italiano, Immunosuppressive, Immunosuppressive therapy, Inactive disease, Inclusion body myositis, Incomplete recovery, Individual patient, Infrequent relapses, Internal medicine, Interstitial lung disease, Ivig, Long term, Lower doses, Lung involvement, Lyme disease, Magnetic resonance imaging, Methotrexate, Muscle biopsies, Muscle biopsy, Muscle disease, Muscle enzymes, Muscle strength, Myocardial involvement, Myopathy, Myositis, Ndings, Oral methotrexate, Other elements, Other forms, Other situations, Overlap group, Plasma exchange, Polymyositis, Poor response, Pulse steroids, Reasonable period, Recent data, Recent experience, Recent report, Recent reports, Recent review, Refractory cases, Relapse, Renal toxicity, Rheumatic diseases, Rheumatoid arthritis, Rheumatology, Skin disease, Soriano, Special consideration, Steroid, Steroid myopathy, Subset, Systemic lupus erythematosus, Therapeutic aspects, Total body irradiation, Toxicity, Uncommon agents.
Abstract
Abstract: The present treatment of the inflammatory myopathies remains unsatisfactory in several areas, perhaps due in part to our incomplete knowledge of their aetiology. These conditions have been grouped together for practical purposes and because of a similar approach to treatment. However, recent data regarding pathological findings, serological patterns and different outcomes, suggest that some of these myopathies may be distinct, and perhaps approaches to treatment should be tailored according to these findings. This chapter will attempt to update our current management, offer an analysis of recent data regarding newer treatment modalities and highlight areas lacking solid data that need to be further addressed. Although corticosteroids are still considered to be the mainstay of treatment, the earlier use of immunosuppressive therapy will be discussed, as will the use of autoantibody profiles for tailoring treatment. Newer modalities for the monitoring of therapeutic response and their current place in clinical practice will be analysed. The management of refractory cases will be addressed as will the current management of calcinosis, a problem more frequently encountered in children.
Url:
DOI: 10.1053/berh.1999.0077
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000169
- to stream Istex, to step Curation: 000169
- to stream Istex, to step Checkpoint: 001343
- to stream Main, to step Merge: 002553
- to stream Main, to step Curation: 002525
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Inflammatory muscle disease: therapeutic aspects</title><author><name sortKey="Catoggio, Luis J" sort="Catoggio, Luis J" uniqKey="Catoggio L" first="Luis J." last="Catoggio">Luis J. Catoggio</name></author><author><name sortKey="Soriano, Enrique R" sort="Soriano, Enrique R" uniqKey="Soriano E" first="Enrique R." last="Soriano">Enrique R. Soriano</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A2B73DB18679E0C117ECCC57CD295526271DF5C8</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1053/berh.1999.0077</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-WWQG92KM-8/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000169</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000169</idno><idno type="wicri:Area/Istex/Curation">000169</idno><idno type="wicri:Area/Istex/Checkpoint">001343</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001343</idno><idno type="wicri:doubleKey">1521-6942:2000:Catoggio L:inflammatory:muscle:disease</idno><idno type="wicri:Area/Main/Merge">002553</idno><idno type="wicri:Area/Main/Curation">002525</idno><idno type="wicri:Area/Main/Exploration">002525</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Inflammatory muscle disease: therapeutic aspects</title><author><name sortKey="Catoggio, Luis J" sort="Catoggio, Luis J" uniqKey="Catoggio L" first="Luis J." last="Catoggio">Luis J. Catoggio</name><affiliation wicri:level="1"><country xml:lang="fr">Argentine</country><wicri:regionArea>Rheumatology Section, Medical Services, Hospital Italiano de Buenos Aires, Gascon 450, 1181, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Soriano, Enrique R" sort="Soriano, Enrique R" uniqKey="Soriano E" first="Enrique R." last="Soriano">Enrique R. Soriano</name><affiliation wicri:level="1"><country xml:lang="fr">Argentine</country><wicri:regionArea>Fundacion Dr Pedro M. Catoggio para el Progreso de la Reumatologia</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Best Practice & Research Clinical Rheumatology</title><title level="j" type="abbrev">YBERH</title><idno type="ISSN">1521-6942</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2000">2000</date><biblScope unit="volume">14</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="55">55</biblScope><biblScope unit="page" to="71">71</biblScope></imprint><idno type="ISSN">1521-6942</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1521-6942</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>autoantibodies</term><term>dermatomyositis</term><term>inclusion body myositis</term><term>inflammatory myopathies</term><term>overlap syndromes</term><term>polymyositis</term><term>therapy</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Accurate diagnosis</term><term>Active disease</term><term>Active exercise</term><term>Adequate treatment</term><term>Aggressive therapy</term><term>Aggressive treatment</term><term>American journal</term><term>Arthritis</term><term>Autoantibody</term><term>Azathioprine</term><term>Biopsy</term><term>Bone marrow suppression</term><term>British journal</term><term>Buenos aires</term><term>Case reports</term><term>Catoggio</term><term>Chloroquine</term><term>Chloroquine sulphate</term><term>Clinical improvement</term><term>Clinical practice</term><term>Combination therapy</term><term>Corticosteroid</term><term>Current management</term><term>Cyclophosphamide</term><term>Cytotoxic drugs</term><term>Dermatomyositis</term><term>Dos</term><term>Drug therapy</term><term>England journal</term><term>Experimental rheumatology</term><term>Foetal loss</term><term>Gamma globulin</term><term>High dose steroids</term><term>High doses</term><term>High risk</term><term>Hospital italiano</term><term>Immunosuppressive</term><term>Immunosuppressive therapy</term><term>Inactive disease</term><term>Inclusion body myositis</term><term>Incomplete recovery</term><term>Individual patient</term><term>Infrequent relapses</term><term>Internal medicine</term><term>Interstitial lung disease</term><term>Ivig</term><term>Long term</term><term>Lower doses</term><term>Lung involvement</term><term>Lyme disease</term><term>Magnetic resonance imaging</term><term>Methotrexate</term><term>Muscle biopsies</term><term>Muscle biopsy</term><term>Muscle disease</term><term>Muscle enzymes</term><term>Muscle strength</term><term>Myocardial involvement</term><term>Myopathy</term><term>Myositis</term><term>Ndings</term><term>Oral methotrexate</term><term>Other elements</term><term>Other forms</term><term>Other situations</term><term>Overlap group</term><term>Plasma exchange</term><term>Polymyositis</term><term>Poor response</term><term>Pulse steroids</term><term>Reasonable period</term><term>Recent data</term><term>Recent experience</term><term>Recent report</term><term>Recent reports</term><term>Recent review</term><term>Refractory cases</term><term>Relapse</term><term>Renal toxicity</term><term>Rheumatic diseases</term><term>Rheumatoid arthritis</term><term>Rheumatology</term><term>Skin disease</term><term>Soriano</term><term>Special consideration</term><term>Steroid</term><term>Steroid myopathy</term><term>Subset</term><term>Systemic lupus erythematosus</term><term>Therapeutic aspects</term><term>Total body irradiation</term><term>Toxicity</term><term>Uncommon agents</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: The present treatment of the inflammatory myopathies remains unsatisfactory in several areas, perhaps due in part to our incomplete knowledge of their aetiology. These conditions have been grouped together for practical purposes and because of a similar approach to treatment. However, recent data regarding pathological findings, serological patterns and different outcomes, suggest that some of these myopathies may be distinct, and perhaps approaches to treatment should be tailored according to these findings. This chapter will attempt to update our current management, offer an analysis of recent data regarding newer treatment modalities and highlight areas lacking solid data that need to be further addressed. Although corticosteroids are still considered to be the mainstay of treatment, the earlier use of immunosuppressive therapy will be discussed, as will the use of autoantibody profiles for tailoring treatment. Newer modalities for the monitoring of therapeutic response and their current place in clinical practice will be analysed. The management of refractory cases will be addressed as will the current management of calcinosis, a problem more frequently encountered in children.</div></front></TEI><affiliations><list><country><li>Argentine</li></country></list><tree><country name="Argentine"><noRegion><name sortKey="Catoggio, Luis J" sort="Catoggio, Luis J" uniqKey="Catoggio L" first="Luis J." last="Catoggio">Luis J. Catoggio</name></noRegion><name sortKey="Soriano, Enrique R" sort="Soriano, Enrique R" uniqKey="Soriano E" first="Enrique R." last="Soriano">Enrique R. Soriano</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002525 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002525 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:A2B73DB18679E0C117ECCC57CD295526271DF5C8
|texte= Inflammatory muscle disease: therapeutic aspects
}}
| This area was generated with Dilib version V0.6.33. |  |